A primary care trust has been ordered to review its decision not fund treatment with a cancer drug.

A primary care trust has been ordered to review its decision not fund treatment with a cancer drug.

Bromley PCT has been told to 'consider afresh' its decision not to fund treatment with Tarceva for Linda Gordon, who has lung cancer.

The court has already ordered the PCT to fund the drug for four weeks. Tarceva is licensed as third-line therapy for lung cancer but has not been appraised by the National Institute for Health and Clinical Excellence.

Ms Gordon's application for a judicial review of the PCT's decision has been dismissed, but the judge said the issue was whether the trust would still refuse funding even if a four-week trial proved successful.

Mr Justice Ousele said: 'It would be to raise false hopes to have a trial and then say ?well, the results don't really affect our decision?.'

A PCT statement said: 'If a fresh request for Tarceva is made by Ms Gordon to fund an individual clinical trial, the PCT has been asked to consider this expressly.'